This phase III study is evaluating the effectiveness of a new targeted therapy (XL092) plus immunotherapy (atezolizumab) compared to a different type of targeted therapy (regorafenib) in people with metastatic colorectal cancer (mCRC).
This trial is treating patients with bowel cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had a certain type of treatment or surgical procedure.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Eligible participants will be allocated to either the Experimental Arm or the Active Comparator Arm. In the Experimental Arm, participants will receive XL092 (administered orally, daily) plus atezolizumab (administered as a 1200mg IV infusion once in a 3-week cycle). In the Active Comparator Arm, participants will receive regorafenib (administered orally daily at 160mg for the first 21 days of each 28-day cycle).
Recruiting Hospitals Read More